PAMELA STUCKEY: Open Payments
NPI 1609299858 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,049 in 75 payments from 34 companies in 2025. Trend: 2023 $1,526 · 2024 $1,508 · 2025 $2,049
Food & beverage: $1,749Long term medical supply or device loan: $199Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 8 | $347 |
| E.R. Squibb & Sons, L.L.C. | 9 | $178 |
| Kite Pharma, Inc. | 1 | $144 |
| AstraZeneca Pharmaceuticals LP | 6 | $128 |
| Celgene Corporation | 5 | $105 |
| SEAGEN INC. | 1 | $100 |
| Merck Sharp & Dohme LLC | 3 | $81 |
| PharmaEssentia USA Corporation | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Janssen Biotech, Inc. | 2 | $61 |
Products named: KISQALI, Yescarta, OPDIVO, OPDUALAG, KEYTRUDA, SCEMBLIX, REBLOZYL, BESREMI.
Industry payments across SC — which companies pay providers there.
